vTv Therapeutics (VTVT) EBITDA (2014 - 2026)

vTv Therapeutics has disclosed EBITDA across 13 years of filings, most recently posting $23.3 million for Q1 2026.

• EBITDA for Q1 2026 came in at $23.3 million, up 457.73% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.0 million (up 87.86% YoY), and the FY2025 annual result was -$32.8 million, down 35.68% from the prior year.
• EBITDA came in at $23.3 million for Q1 2026 at vTv Therapeutics, up from -$7.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $23.3 million in Q1 2026 to a low of -$10.7 million in Q3 2025.
• The 5-year median for EBITDA is -$6.5 million (2022), against an average of -$4.8 million.
• Across the five-year window, EBITDA plunged 254.9% in 2022 and surged 457.73% in 2026, its largest moves.
• vTv Therapeutics' EBITDA stood at -$6.3 million in 2022, then gained by 25.79% to -$4.7 million in 2023, then dropped by 3.93% to -$4.9 million in 2024, then slumped by 61.18% to -$7.9 million in 2025, then jumped by 395.03% to $23.3 million in 2026.
• The last three EBITDA figures came in at $23.3 million (Q1 2026), -$7.9 million (Q4 2025), and -$10.7 million (Q3 2025), per Business Quant data.